If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service d'Accueil des Urgences and Sorbonne Universités GRC-14 BIOSFAST et INSERM UMR-S 1166, Paris, France
AP-HP.Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Médecine Intensive Réanimation, Institut de Cardiologie and Sorbonne Université, INSERM, UMRS_1166-ICAN Institut de Cardiométabolisme et Nutrition, Paris, France
Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses, Paris, France
Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, 83 boulevard de l'hôpital, F 75013 Paris, France
In this Journal, Zheng et al. have report the symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection -named coronavirus disease 2019 (COVID-19)- appear very similar to influenza.
It is important to facilitate differential diagnosis. We therefore conducted a retrospective study to further explore specific features and to better characterize risk factors for severe illness.
This retrospective study included 200 inpatients from the Pitié-Salpêtrière University Hospital (Paris, France) with SARS-CoV-2 (n = 100, ‘COVID-19 group’) or influenza (n = 100, ‘influenza group’) laboratory-confirmed infections on respiratory specimens between January 1st-March 25th, 2020. Patients with complete baseline clinical and biological available data were consecutively included. The study was approved by the Comité Ethique de la Recherche of Sorbonne University (approval number CER 2020–44). Demographic, biological, treatment, and clinical outcome data were extracted from medical records using a standardized form. We collected date of symptom onset, comorbidities, radiographic findings upon admission, and relevant data concerning hospital courses (overall duration of stay, and transfer in intensive care unit [ICU] and supportive care ward). Clinical outcomes were monitored up to April 11th, final date of follow-up. Overweight/obesity was defined as body mass index (BMI) >25 kg/m2.
Variables are presented as ‘median’ (interquartile ranges; IQR) or ‘number of’ (%). We used the Mann-Whitney U test, χ2 test, or Fisher's exact test to compare groups, where appropriate. A two-sided α<0.05 was considered as statistically significant. Risk factors were analyzed by logistic regression analysis. We excluded variables from univariable analysis if their between-group differences were not statistically significant. Variables for multivariable analysis were chosen if p<0.20 in univariable analysis and if the number of events was sufficient to calculate odds ratios (OR). Analyses were performed using GraphPad Prism v.8.
Baseline characteristics of the 200 patients included are shown in the Table 1. Overall, the median age was 60 (IQR=50–73; 42 females) and 61 (48–76; 44 females) in COVID-19 and influenza groups, respectively. Comorbidities were present in the majority of patients (>89%) with diabetes, hypertension, and overweight/obesity as most common comorbidities. However, influenza patients were more likely to have chronic pulmonary diseases (p = 0.01). Overweight/obesity rate (p = 0.02) and median BMI (p = 0.04) were significantly higher in COVID-19. At the time of diagnosis, the most frequent symptoms were fever (p = 0.63) and cough (p = 1.00) in both groups. COVID-19 patients complained more significantly about fatigue, faintness, diarrhea, and anosmia/ageusia. Conversely, sputum production (p = 0.0001) and nasal congestion (p = 0.02) were reported most frequently in influenza. The frequency of patients presenting with respiratory failure were similar in both groups (around 10.0%). However, secondary respiratory failure were only observed in COVID-19 (21%; p<0.0001). COVID-19 patients experienced more often acute kidney failure (p = 0.048) and pulmonary embolism (p = 0.03). Heart congestion was more frequent in influenza (p = 0.003). Notably, ground-glass opacities showed a trend towards higher frequency in COVID-19 patients, although not statistically significant (p = 0.06). Conversely, pulmonary nodules were much more observed in influenza (p = 0.001). Influenza patients had statistically higher levels of white blood cells, neutrophils, platelets, sodium, troponin, albumin than COVID-19 patients (Table 1). Both groups exhibited lymphocytopenia (around 80% of patients) (data not shown), however no significant median value difference was observed.
Table 1Overall baseline characteristics of patients with COVID-19 or influenza.
Biological data from patients with COVID-19 and Influenza infection were available for hematological values in 100 patients, fibrinogen in 44 and 46 patients, sodium and potassium in 96 and 98 patients, chloride in 96 and 95 patients, bicarbonates in 79 and 85 patients, troponin in 32 and 35 patients, albumin in 7 and 24 patients, C-reactive protein in 64 and 73 patients, serum creatinine in 98 and 98 patients, total bilirubin in 44 and 65 patients, aspartate aminotransferase in 51 and 70 patients, alanine aminotransferase in 51 and 71 patients, ʏ-glutamyltransferase in 48 and 69 patients, creatine kinase in 23 and 34 patients, lactate dehydrogenase in 21 and 34 patients, arterial lactates in 51 and 36 patients, procalcitonin in 60 and 74 patients, arterial blood pH in 48 and 35 patients, respectively. BMI: body mass index; COVID-19: coronavirus disease 2019; CT: computed tomography; CV: cardiovascular; HBV: hepatitis B virus; HIV: human immunodeficiency virus; ICU: intensive care unit; IQR: interquartile range; no.: number of. p<0.05 was considered to be statistically significant.
White-cell count (G/L; 4.00 – 10.00)
5.88 (4.41–7.68)
6.72 (5.15–9.42)
0.01
Neutrophils (G/L; 2.00– 7.50)
4.11 (2.99–5.65)
5.06 (3.43–7.25)
0.02
Lymphocytes (G/L; 1.50–4.00)
1.08 (0.68–1.41)
0.89 (0.66–1.35)
0.41
Hemoglobin (g/dL; 13.0–17.5)
13.6 (12.2–14.5)
13.2 (11.6–14.3)
0.29
Platelets (G/L; 150–400)
179 (145–225)
199 (168–239)
0.04
Fibrinogen (g/L; 2–4)
5.5 (4.2–6.7)
5.4 (4.5–6.4)
0.92
Activated partial thromboplastin time (s; <1.20)
1.16 (1.10–1.30)
1.14 (1.04–1.29)
0.44
Prothrombin time (%; 70–120)
98 (86–100)
91 (76–100)
0.08
Sodium (U/L; 136–155)
137 (135–139)
138 (136–140)
0.006
Potassium (U/L; 3.4–5.1)
4.1 (3.8–4.6)
4.0 (3.7–4.4)
0.09
Chloride (U/L; 98–107)
99 (97–102)
100 (97–103)
0.35
Bicarbonates (mmol/L; 22 – 26)
24 (22–26)
25 (23–27)
0.07
Troponin (ng/L; <0.60)
9.2 (6.5–22.4)
34.4 (8.8–72.2)
0.007
Albumin (g/L; 35–52)
30 (27–33)
37 (33–39)
0.04
C-reactive protein (mg/L; <5.0)
47.37 (15.42–87.46)
41.44 (15.25–82.05)
0.55
Serum creatinine (µmol/L; 62–106)
86 (70–117)
87 (70–108)
0.75
Total bilirubin (µmol/L; 2–17)
8 (5–12)
8 (5–12)
0.99
Aspartate aminotransferase (U/L; 20–32)
45 (34–76)
34 (29–49)
0.02
Alanine aminotransferase (U/L; 16– 35)
31 (22–59)
26 (20–42)
0.21
γ -glutamyltransferase (U/L; 12–55)
44 (26–101)
32 (21–54)
0.08
Creatine kinase (U/L; <190)
178 (109–473)
117 (65–378)
0.42
Lactate dehydrogenase (U/L; 135–215)
397 (305–544)
298 (248–383)
0.04
Arterial lactates (mmol/L; 0.5–1.8)
1.0 (0.7–1.4)
1.2 (0.9–1.4)
0.09
Procalcitonin (µg/L; <0.10)
0.12 (0.08–0.27)
0.13 (0.07–0.36)
0.74
Arterial blood pH (7.35–7.45)
7.45 (7.42–7.48)
7.43 (7.40–7.78)
0.33
Treatments – no./total no. (%)
Oseltamivir
11/95 (11.6)
45/97 (46.4)
<0.0001
Any antibiotics
77/98 (78.6)
58/97 (59.8)
0.005
Amoxicillin/Clavulanic acid
40/98 (40.8)
33/97 (34.0)
0.37
Cephalosporin
48/98 (49.0)
21/97 (21.6)
<0.0001
Oxygen therapy
65 (65.0)
42/99 (42.4)
0.002
Complications – no./total no. (%)
Pulmonary embolism
6 (6.0)
0
0.03
Acute kidney failure
17 (17.0)
7 (7.0)
0.048
Myocarditis
0
2 (2.0)
0.50
Heart congestion
2 (2.0)
14 (14.0)
0.003
Heart rhythm disorder
7 (7.0)
2 (2.0)
0.17
Clinical outcomes at data cutoff no./total no. (%)
Admitted in ICU
31 (31.0)
12 (12.0)
0.002
Discharged
75 (80.0)
94 (94.0)
0.0003
Death
20 (20.0)
5 (5.0)
0.002
Remained in hospital
5 (5.0)
1 (1.0)
0.21
# Denominators of patients included in this analysis are shown if they differed from the overall numbers in the respective group.
‡ Data regarding BMI medians were available for 56 and 48 patients in COVID-19 and influenza groups, respectively.
¤ For each biological variable, the number of digits after decimal point depends on technical precision.
§ Biological data from patients with COVID-19 and Influenza infection were available for hematological values in 100 patients, fibrinogen in 44 and 46 patients, sodium and potassium in 96 and 98 patients, chloride in 96 and 95 patients, bicarbonates in 79 and 85 patients, troponin in 32 and 35 patients, albumin in 7 and 24 patients, C-reactive protein in 64 and 73 patients, serum creatinine in 98 and 98 patients, total bilirubin in 44 and 65 patients, aspartate aminotransferase in 51 and 70 patients, alanine aminotransferase in 51 and 71 patients, ʏ-glutamyltransferase in 48 and 69 patients, creatine kinase in 23 and 34 patients, lactate dehydrogenase in 21 and 34 patients, arterial lactates in 51 and 36 patients, procalcitonin in 60 and 74 patients, arterial blood pH in 48 and 35 patients, respectively.BMI: body mass index; COVID-19: coronavirus disease 2019; CT: computed tomography; CV: cardiovascular; HBV: hepatitis B virus; HIV: human immunodeficiency virus; ICU: intensive care unit; IQR: interquartile range; no.: number of. p<0.05 was considered to be statistically significant.
The median time from illness onset to admission was 4 [1–6] and 2 [0–4] days for COVID-19 and influenza, respectively (p = 0.02, Fig. 1). COVID-19 patients more frequently required hospitalization (p = 0.001) (data not shown). Noteworthy, the median duration of overall hospital stay was significantly longer for COVID-19 than for influenza (10 [4–17] and 4 [1–11] days, respectively, p<0.0001). Overall, COVID-19 patients more frequently required oxygen therapy (p = 0.002) (Table 1). The median duration between onset of symptoms and aggravation was 7 (5–10) and 4 (2.5–6) days in COVID-19 and influenza groups, respectively (p<0.0001) (data not shown). Clinical worsening was linked to a higher ICU rate admission among COVID patients (p = 0.002). Baseline characteristics, clinical courses, outcome, and duration from illness onset concerning severe infections (31 and 12 severe COVID-19 and influenza, respectively) are shown in Supplementary Tables 1–3/Fig. 1. Noteworthy, no significant difference was evidenced concerning corticosteroid use comparing both severe infection groups (p = 0.84).
Fig. 1Duration from illness onset and clinical courses in COVID-19 (n = 100) and influenza groups (n = 100)
Histograms represent duration in days of symptoms before admission (blue), stay out of ICU (light pink), stay in ICU for severe cases (red), and in post-ICU supportive care wards (yellow). n represent the number of concerned patients according to type of hospitalization. The median time from illness onset (i.e. before admission) to admission was 4 days [IQR: 1–6] and 2 days [IQR: 0–4] for COVID-19 and influenza patients, respectively (p = 0.02). The median time of hospitalization out of ICU was 5 days [IQR: 1–10] and 1 day [IQR: 0–8] for COVID-19 and influenza patients, respectively (p = 0.0112). Overall, 20 and 5 patients died in both groups, respectively. Among ICU-hospitalized patients (31 COVID-19 and 12 influenza), 11 and 3 patients died in both groups, respectively. * symbolizes significant differences between COVID-19 and influenza groups. COVID-19: coronavirus disease 2019; ICU: intensive care unit. p<0.05 was considered to be statistically significant.
In multivariable analysis, odds of severe COVID-19 were significantly higher in individuals with chronic lung disease (OR=6.45; p = 0.009), hypertension (3.05; p = 0.02), and overweight/obesity (3.23; p = 0.02). Obstructive sleep apnea and overweight/obesity were significantly associated with severe influenza in univariable analysis (p = 0.04 and p = 0.04, respectively) (Supplementary Tables 4–5). The mortality rate was significantly higher in COVID-19 group than in influenza group (20% vs. 5%; p = 0.002). Age and diabetes appear as death risk factors in COVID-19 in multivariable analysis (OR=1.06 [95% CI=1.02–1.11]; p = 0.004 and OR=4.50 [1.48–14.24]; p = 0.009, respectively) (Supplementary Table 6).
To the best of our knowledge, this study is the largest case series to date comparing COVID-19 and influenza. COVID-19 patients more frequently reported dry cough, asthenia, diarrhea, anosmia/ageusia, and clinical worsening around 7 days after symptom onset, as previously described
We reported more severe cases requiring oxygenation therapy, a higher death rate, and a longer hospital stay in COVID-19 group. Moreover, COVID-19 patients also experienced disease aggravation around 7 days post-symptom onset, as previously reported.
however, COVID-19 patients developed preferentially secondary respiratory failure. Interestingly, inflammation marker levels were significantly higher in severe COVID-19 cases. It is well established that SARS-CoV-2 triggers an excessive harmful proinflammatory response
In our study, pulmonary embolism was only reported during COVID-19 (p = 0.03). COVID-19 and influenza patients commonly share overweight/obesity as risk factor for severe infection.
As previously reported, pre-existing hypertension and diabetes were additionally associated with a higher risk to develop severe COVID-19. Similarly, our study also confirmed older age and diabetes as major contributing death risk factors in COVID-19.
To conclude, we described similarities but also differences between COVID-19 and influenza, thereby providing some guidance for healthcare management.
Contributors
HF and MP had the idea for and designed the study. HF, MP, CC, and SB and had full access to the collected data and take responsibility for the integrity of the data and the accuracy of the data analysis. PH, CEL, MD, and VP assessed the accuracy of clinical data. HF, CC, and AJ processed statistical data. HF, CC, MP, DB, and SB drafted the paper. All authors critically revised the manuscript for intellectual content and gave final approval for the submitted version.
Declaration of Competing Interest
We declare no competing interests.
Acknowledgments
We acknowledge all healthcare workers involved in the diagnosis and treatment of patients.
30551-X&id=gr1.jpg){kind=link}